

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 7, 2022**

**8i Acquisition 2 Corp.**

(Exact Name of Registrant as Specified in its Charter)

**British Virgin Islands**

(State or other jurisdiction  
of incorporation)

**001-40462**

(Commission  
File Number)

**n/a**

(I.R.S. Employer  
Identification No.)

c/o 6 Eu Tong Seng Street  
#08-13 Singapore 059817

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **+65-6788 0388**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of one Ordinary Share, and one Right to acquire one-tenth of an Ordinary Share	LAXXU	NASDAQ Stock Market LLC
Ordinary Shares included as part of the Units	LAX	NASDAQ Stock Market LLC
Redeemable Warrants included as part of the Units	LAXXW	NASDAQ Stock Market LLC
Rights included as part of the Units	LAXXR	NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 7.01 Regulation FD Disclosure.

As previously announced, 8i Acquisition 2 Corp., a British Virgin Islands business company (“LAX”), entered into a Share Purchase Agreement (the “SPA”) dated April 11, 2022, as amended on May 30, 2022, and June 10, 2022, with Euda Health Limited, a British Virgin Islands business company (“EUDA Health”), Watermark Developments Limited, a British Virgin Islands business company, and Kwong Yeow Liew, acting as representative of the indemnified parties. Pursuant to the terms of the SPA, a business combination between LAX and EUDA Health will be effected through the purchase by LAX of all of the issued and outstanding shares of EUDA Health from the Seller (the “Share Purchase”).

Furnished as Exhibit 99.1 and Exhibit 99.2 are the updated investor presentation and updated executive summary of the investor presentation, respectively, that will be used by LAX and EUDA Health in connection with the Share Purchase, the SPA, and related matters.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

### Important Information for Investors and Shareholders

This document relates to a proposed transaction between LAX and EUDA Health. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. LAX has filed a preliminary proxy statement with the SEC. A proxy statement will be sent to all LAX shareholders. LAX also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of LAX are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by LAX through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov).

### Forward Looking Statements

Certain statements included in this Current Report on Form 8-K are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of LAX’s and EUDA Health’s respective management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of LAX and EUDA Health. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.

---

These forward-looking statements are subject to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in the prospectus filed by LAX in connection with its initial public offering on November 22, 2021. Important factors, among others, that may affect actual results or outcomes include: the inability of the parties to successfully or timely consummate the Share Purchase, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect EUDA Health or the expected benefits of the Share Purchase, if not obtained; the failure to realize the anticipated benefits of the business combination; matters discovered by the parties as they complete their respective due diligence investigation of the other parties; the ability of LAX prior to the Share Purchase, and EUDA Health following the Share Purchase, to maintain the listing of LAX’s shares on Nasdaq; costs related to the business combination; the failure to satisfy the conditions to the consummation of the Share Purchase, including the approval of the SPA by the shareholders of LAX, the satisfaction of the minimum cash requirements of the SPA following any redemptions by LAX’s shareholders; the risk that the Share Purchase may not be completed by the stated deadline and the potential failure to obtain an extension of the stated deadline; and the outcome of any legal proceedings that may be instituted against LAX or EUDA Health related to the business combination. Important factors that could cause the combined company’s actual results or outcomes to differ materially from those discussed in the forward-looking statements include: EUDA Health’s limited operating history and history of net losses; EUDA Health’s ability to manage growth; EUDA Health’s ability to execute its business plan; EUDA Health’s estimates of the size of the markets for its products; the rate and degree of market acceptance of EUDA Health’s products; EUDA Health’s ability to identify and integrate acquisitions; potential litigation involving the Company or EUDA Health or the validity or enforceability of EUDA Health’s intellectual property; and general economic and market conditions impacting demand for EUDA Health’s products and services.

If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither LAX nor EUDA Health presently know, or that LAX and EUDA Health currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LAX and EUDA Health’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this Current Report on Form 8-K and the attachments hereto should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K and the attachments hereto, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors of LAX and EUDA Health described above. LAX and EUDA Health anticipate that subsequent events and developments will cause their assessments to change. However, while LAX and EUDA Health may elect to update these forward-looking statements at some point in the future, they each specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing LAX or EUDA Health’s assessments as of any date subsequent to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.

#### **Participants in the Solicitation**

LAX and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from LAX’s shareholders with respect to the proposed transaction. Information regarding LAX’s directors and executive officers is available in its prospectus filed in connection with its initial public offering on November 22, 2021. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests will be contained in the proxy statement when it becomes available.

EUDA Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of LAX in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement for the proposed transaction when available. You may obtain free copies of these documents as described in the second paragraph under the above section entitled “Important Information for Investors and Shareholders.”

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

---

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits:**

<b>Exhibit</b>	<b>Description</b>
99.1	<a href="#">Investor Presentation dated July 2022</a>
99.2	<a href="#">Executive Summary of Investor Presentation dated July 2022</a>
104	Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 7, 2022

8i Acquisition 2 Corp.

By: /s/ Meng Dong (James) Tan

Name: Meng Dong (James) Tan

Title: Chief Executive Officer

---



Corporate Presentation July 2022

Strictly Private & Confidential



# Confidentiality and Disclaimer

This confidential presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the "proposed business combination") between Euda Health Limited ("EUDA") and 8i Acquisition 2 Corp ("8i" or the "SPAC") and related transactions and for no other purpose. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute financial investment, tax or legal advice. To the fullest extent permitted by law in no circumstances will EUDA, 8i or any of their respective subsidiaries, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this presentation, its contents, its omissions, errors, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. No representations or warranties, express or implied, is or will be given by EUDA, 8i or any of their respective affiliates, directors, officers, employees or advisors or any other person as to the accuracy, completeness, reasonableness of statements, estimates, targets, projections, assumptions or judgments in this presentation, or in any other written, oral or other communications transmitted otherwise made available to any part in the course of its evaluation of a possible transaction, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. Industry and market data used in this presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither EUDA nor 8i has independently verified the data obtained from these sources and cannot assure you of the accuracy or completeness of the data. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of EUDA or the proposed business combination. Viewers of this presentation should each make their own evaluation of EUDA and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. EUDA and 8i disclaim any duty to update the information contained in this presentation.

The information in this presentation is highly confidential. The distribution of this presentation by an authorized recipient to any other person is unauthorized. Any photocopying, disclosure, reproduction or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. The recipient of this presentation shall keep this presentation and its contents confidential, shall not use this presentation and its contents for any purpose other than as expressly authorized by EUDA and 8i and shall be required to return or destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements. This presentation contains trademarks, service marks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.

# Forward-Looking Statements

This document includes certain statements, estimates, targets, forward-looking statements, and projections (collectively, "forward-looking statements") that reflect assumptions made by EUDA concerning anticipated future performance of EUDA and its industry. Such forward-looking statements are based on significant assumptions and subjective judgments concerning anticipated results, which are inherently subject to risks, variability, and contingencies, many of which are beyond EUDA's control. Factors that could cause actual results to differ from these forward-looking statements include, but are not limited to, general economic conditions, the availability and terms of financing, the effects and uncertainties created by the ongoing COVID-19 pandemic, EUDA's limited operating history, changes in regulatory requirements and governmental incentives, competition, and other risks and uncertainties associated with EUDA's research and development activities and commercial production and sales. Such forward-looking statements may be identified by the use of words like "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "will", "should", "seek" and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. EUDA shall not undertake any duty to update these forward-looking statements, or the other information contained in this presentation. EUDA does not make any representation or warranty, express or implied, as to the accuracy or completeness of this document or any other information (whether written or oral) that has been or will be provided to you. Nothing contained herein or in any other oral or written information provided to you is, nor shall be relied upon as, a promise or representation of any kind by EUDA. Without limitation of the foregoing, EUDA expressly disclaims any representation regarding any projections concerning future operating results or any other forward-looking statement contained herein or that otherwise has been or will be provided to you. EUDA shall not be liable to you or any prospective investor or any other person for any information contained herein or that otherwise has been or will be provided to you, or any action heretofore or hereafter taken or omitted to be taken, in connection with this potential transaction. These forward-looking statements also involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted in connection with any proposed business combination; (2) the inability to complete any business combination; (3) delays in obtaining, or inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete any business combination; (4) the risk that any proposed business combination disrupts current plans and operations; (5) the inability to recognize the anticipated benefits of any proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and partners and retain key employees; (6) costs related to any proposed business combination; (7) changes in the applicable laws or regulations; (8) the possibility that EUDA or the Combined Company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) other risks and uncertainties separately provided to the recipient and indicated from time to time described in 8i's filings and future filings by EUDA, 8i and the Combined Company with the U.S. Securities and Exchange Commission. EUDA and 8i caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. EUDA and 8i undertake no obligation to and accepts no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

**No Offer Or Solicitation:** This communication does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with the Proposed Investment or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful.

**Private Placement:** The securities to which this presentation relates have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction. This presentation relates to securities that EUDA would intend to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense.



# Forward-Looking Statements

**Use of Projections:** This presentation contains projected financial information with respect to EUDA. Such projected financial information contains forward-looking information and is for illustration purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecasts information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in the presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved.

**Financial Information; Non-GAAP Financial Terms:** The financial information and data contained in this presentation is unaudited and does not conform to Regulation S-X promulgated by the Securities and Exchange Commission ("SEC"). Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement or registration statement or other report or document to be filed by 8i with the SEC. Furthermore, some of the projected financial information and data contained in this presentation, such as adjusted EBITDA (and related measures), has not been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). 8i and EUDA believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to EUDA's financial condition and results of operations. EUDA's management uses these non-GAAP measures for trends analyses and for budgeting and planning purposes. 8i and EUDA believe that use of these non-GAAP measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing EUDA's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of EUDA does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in EUDA's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. You should review EUDA's audited financial statements, which will be presented in 8i's proxy statement to be filed with the SEC, and not rely on any single financial measure to evaluate EUDA's business. A reconciliation of non-GAAP financial measures in the presentation to the most directly comparable GAAP financial measures is not included because, without unreasonable effort, EUDA is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate these non-GAAP financial measures.

**Trademarks:** This presentation contains trademarks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.

**Additional Information and Where to Find It:** This document relates to a proposed transaction between 8i and EUDA. 8i intends to file a proxy statement which will be sent to all 8i shareholders. 8i also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of 8i and EUDA are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by 8i through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). In addition, the documents filed by 8i may be obtained free of charge from 8i's website at [www.8iac.com](http://www.8iac.com) or by written request to 8i at 6 Eu Tong Sen Street, #08-13 Singapore 059817.

**Participants in Solicitation:** 8i and EUDA and their respective directors and officers may be deemed to be participants in the solicitation of proxies from 8i's shareholders in connection with the proposed transaction. Information about 8i's directors and executive officers and their ownership of 8i's securities is set forth in 8i's filings with the SEC, including 8i's Registration Statement on Form S-1, which was filed with the SEC on November 9, 2021. To the extent that holdings of 8i's securities have changed since the amounts printed on 8i's Registration Statement on Form S-1, such changes will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of these persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.



# Transaction Overview

Strictly Private & Confidential



# Transaction Summary

## Transaction Structure

The transaction is expected to close in Q4 2022

Post-closing, the combined company will be listed on Nasdaq under ticker symbol "EUDA"

## Valuation

- Pro forma enterprise value of the combined company is expected to be approximately \$172M with cash on hand of approximately \$90M, assuming no redemptions.
- Implies attractive entry multiples of 8.6x 2023 Revenue and 37.7x 2023 EBITDA; 4.3x 2024 Revenue and 13.8x 2024 EBITDA
- Proceeds from the transaction will be product development and other AI technology research, business expansion, and potential strategic investment opportunities.

### Pro Forma Valuation (U.S.\$M)

Share Price	\$10.00
Pro forma shares outstanding (mm)	26.2
<b>Pro Forma Equity Value</b>	<b>\$262</b>
Less cash to balance sheet	\$90
<b>Pro Forma Enterprise Value</b>	<b>\$172</b>

## Capital Structure


The transaction is funded by the issuance of 14M new shares to EUDA shareholders at a deemed value of \$10 per share. Existing EUDA shareholders are rolling 100% of their equity and will own 54% of the pro forma equity at closing.

Additional earn-outs of up to 4M shares in total will be issued to EUDA shareholders by:


- achieving the below stock price milestones on any 20 trading days out of 30 trading days post-closing:
  - ✓ Year 1: 1M shares on which share price is  $\geq$  \$15
  - ✓ Year 2: 1M shares on which share price is  $\geq$  \$20
- achieving the Consolidated Revenue and Net Income:
  - ✓ FY2023: 1M shares on which Revenues are  $\geq$  \$20.1M & Net Income of  $\geq$  \$3.6M
  - ✓ FY2024: 1M shares on which Revenues are  $\geq$  \$40.0M & Net Income of  $\geq$  \$10.1M

## Ownership

### Pre-Combination Ownership



### Pro-Forma Ownership



\* Includes shares held by BI Holdings 2 Pte Ltd and Mr. James Tan, BI's CEO and Chairman

# Target Summary

## EUDA Health is positioned to disrupt a fast-growing industry ready for

### Offering Size and Target Profile

- SPAC has \$86.25mm of cash in trust
- Seeks to invest in companies with existing footprints in Asia with the potential to scale their businesses across multiple countries through up-and-coming technology trends such as artificial intelligence, internet of things, encryption, and mobile internet.

### Market Opportunity

- Healthcare expenditure in Asia Pacific is projected to grow by 7% annually to US\$2.4 trillion by 2022
- Growing need to eliminate travel time, consultation wait time, and provide underserved segments wider access to healthcare.
- Health-tech usage in Southeast Asia grew 400% in 2020 with user engagement persisting post-lockdown.

Source: L.E.K.: Expanding into Asia-Pacific; Market Data Forecast


### Financial Highlights

- Projected five-year compound annual growth rate of 98% (2022-2026)
- Long term EBITDA margins of 31%

### EUDA Health Business Overview

- Believed to be first-of-its-kind HealthTech company in Southeast Asia offering healthcare solutions that strengthen delivery for effective care outcomes
- Operates on a proprietary unified AI platform, delivering better care and improving the patient experience
- Fully integrated ecosystem for individuals, doctors and employers
- Patients have more personalized, affordable care and improved healthcare outcomes utilizing data and technology

### Financial Forecasts (FY2022 – 2026)



Notes:

- Forecasts are based on Base scenario which projects existing services to further expand in Singapore. The existing services are Medical Urgent Care, Property Management Services and Euda Society (Doctor's Insurance).
- The Property Management Service covers the management of properties such as condominiums and shopping malls. Categorized under Home Care Service line from 2023 onward, this service line will eventually evolve to provide home-based medical services to households.
- Growth rates are based on the following assumptions:
  - Economies of scale (expansion of healthcare, lifestyle & wellness service lines and enablement in Singapore);
  - Cross-selling opportunities between the service vertical; and
  - Southeast Asia demands i.e., addressing gaps in the identified markets.
- Surge in revenue growth is aligned with our projected expansion timeline.



# Mission & Vision

Strictly Private & Confidential

---

# Our Mission and Vision

## Objectives and goals of our business

### Mission



**Make healthcare more affordable and accessible for all our patients, improve patient experience, and deliver improved healthcare outcomes through personalized care.**



**Aim to provide a one-stop healthcare and wellness service platform**

### Vision



**Leverage our disruptive technology to elevate the quality of healthcare through total care.**

# Competitive Strengths





# Industry Overview

Strictly Private & Confidential





# Industry Challenges

## Rising healthcare spend for insufficient services in an overburdened system

### Healthcare spending outpaced economic growth



Global GDP grew by 3.0% a year

Between 2000 and 2017

2000



2017

Global health spending in real terms grew by 3.9% a year

Source: WHO - Global Spending on Health: A World in Transition, 2019

### Lack of access to healthcare

Density of Doctor per 1,000 people



Source: OECD Health Statistics

### Aging population straining healthcare resources



The East and South-East Asia Region currently hold about **37%** of the world's population age 65 or above.

By 2025,



10% of Asia's population will be 65 years old and above, a 14% growth over 2021



There will be close to half a billion people aged 65 or above in Asia-Pacific.

Source: United Nations - World Population Ageing, 2019

### Poor medical experience



**72%** of the people in Asia Pacific consider wait times to be one of the primary issues in the healthcare delivery system

### Poor medical service experience

4 hours

Average time to visit a doctor



10 mins

Actual time spent in a doctor consultation

Source: L.E.K. - Expanding into Asia-Pacific and Nikkei Asian Review

# Our Opportunities

## The ever-increasing need for technological innovation in healthcare

### Primed for healthcare disruption

In Southeast Asia, the COVID-19 pandemic has accelerated Internet usage



Source: Market Data Forecast; McKinsey & Company; The future of healthcare in Asia: Digital health ecosystems

### Accelerated consumer adoption of health-tech

Advantages of health-tech adoption:

- Elimination of travel time and consultation wait time
- Alleviated the load on healthcare systems
- Prioritized hospitals for patients with more critical illnesses
- Wider access to healthcare for under-served segments




In Southeast Asia, health-tech usage has grown by **400% in 2020** and has retained its users post-lockdown

Source: Google, Temasek, Bain & Company - e-Economy SEA, 2020

### Platform to improve health and wellness

Chronic diseases remain a significant burden on healthcare systems globally



**Diabetes**

Diabetic Population in APAC

241 million in 2017

334 million by 2045

~9 times that of the U.S diabetic population



Our healthcare ecosystem platform coupled with an extensive network of medical partners, our healthcare ecosystem platform will promote fitness and dietary guidelines to a wider pool of consumers

Source: L.E.K.: Expanding into Asia-Pacific, L.E.K. research and analysis, WHO, United Nations Population Fund, GLOBOCAN, MIMS, International Diabetes Federation, Alzheimer's Disease International, South China Morning Post, Shao et al. (2016), Singapore Business Review



# Business Overview

Strictly Private & Confidential



# Business Overview

## Reimagining the Future of Modern Healthcare


### Overview

Believed to be first-of-its-kind HealthTech company offering healthcare solutions in Southeast Asia that strengthen delivery for effective care outcomes.

Operates on a proprietary unified AI platform that streamlines communication and information flow to deliver better care and improve patient experience.

Fully integrated ecosystem for individuals, doctors, insurers and employers.

Patients have more personalized, more affordable care and improved clinical outcomes utilizing data and technology.




2019

Established



# Our Ecosystem-Based Approach

Aimed to serve the Full Spectrum of Care & Wellness and Bridge the Healthcare Delivery System



# Comprehensive Solutions Provider for Consumers

## Digital Health systems enabling a range of Consumer-Centric services



Holistic care platform and global network



State of the art blockchain solutions\*



Unparalleled support



Scalable data-driven EUDA platform



### Cloud-based Decision Support System

Proprietary algorithm to perform digital triage, smart matching, remote patient management and AI-powered treatment recommendations



### Smart Wearable Solutions

Remote care kits with "plug and play" capabilities that enable the wireless connectivity and seamless transfer of medical data



### Serverless Blockchain\*

Secure and reliable transmission of health records, payments and patient information




### Engaging Healthcare Super App

Effective guided achievement optimize user experience


\* In development 17

# Believed to be first Of-its-kind Analytics Platform Dedicated To Healthtech in Southeast Asia

## Innovative, Interactive and Dynamic Solutions




# Enhanced User Journey Experience





## EUDA Healthcare Ecosystem

### Leveraging our end-to-end expertise in healthcare management to orchestrate the healthcare journey




01 **Orchestrating the healthcare ecosystem** with a unique value proposition, based on end-to-end expertise in healthcare management

02 **Improved efficiency** of the healthcare orchestration can lead up to 40% savings for the patient  
Source: Aidoc: Why an AI OS is critical to the future of hospitals


03 Providing healthcare analytics, taking advantage of state-of-the-art big data, machine learning & AI capabilities to predict health outcomes early

## Reliable Accuracy Through Next Generation Technology\*



# Sustainable and Diversified Revenue Model

## Current Revenue Streams



<sup>1</sup> Based on 2022Q1 results


\* Upcoming

22


EUDA  
HEALTH

# Sustainable and Diversified Revenue Model

## Projected Multiple Monetization Channels



# Competitor Matrix



# Our Management Team

## Visionary Leadership Team



**Dr Kelvin Chen**  
Founder & CEO

Dr Kelvin Chen has amassed over **15 years** of experience in executive management and in the healthcare sector. He was the former SVP of Healthway Medical.

He holds a Doctorate in Business Administration from the University of South Australia and graduated from University of Greenwich, with a Bachelor's Degree in Computer Science.



**Jenifer Goh**  
President of Operations

Ms Goh has amassed over **10 years** of experience in healthcare marketing & operations, and insurance.

She is currently leading the corporate improvement projects and initiatives that will bring about better health and better value for the health plans.



**Steven John Sobak**  
Chief Financial Officer

Mr Sobak has over **50 years** of experience in healthcare administrative experience covering most aspects of hospital management in both the public and private sectors, in general acute and various specialty facilities.

He holds a Master's Degree in Finance.



**Daniel Tan**  
Chief Technology Officer

Mr Tan has more than **15 years** of experience in high-tech industries including Autonomous Vehicles Development, Complex Underwater Defense Systems and Logistics Platform Technologies.

He holds a Masters in Systems Design & Management from National University of Singapore and multiple professional certifications in Project Management & ITIL.



**Dr Keith Lee**  
Medical Director

Dr Keith completed his medical degree at the National University of Singapore in 2007 and has been in clinical practice since. He has been active in the medical line for more than **15 years**.


He successfully obtained his Orthopedic Surgery fellowship from the Royal College of Surgeons Edinburgh in 2017.



# Financial Performance

## Strong Underlying Business Model

Historical Financials, USD'M






# Financial Forecast

## For FY2022 to FY2026

Financial Forecast, USD'M



**Notes:**

- Forecasts are based on Base scenario which projects existing services to further expand in Singapore. The existing services are Medical Urgent Care, Property Management Services and Euda Society (Doctor's Insurance).
- The Property Management Service covers the management of properties such as condominiums and shopping malls. Categorized under Home Care Service line from 2023 onward, this service line will eventually evolve to provide home-based medical services to households.
- Growth rates are based on the following assumptions:
  - Economies of scale (expansion of healthcare, lifestyle & wellness service lines and enablement in Singapore);
  - Cross-selling opportunities between the service vertical; and
  - Southeast Asia demands i.e., addressing gaps in the identified markets.
- Surge in revenue growth is aligned with our projected expansion timeline.


# Financial Forecast

## Revenue Breakdown

### Three broad service care lines in Singapore:


- ▶ Healthcare – Medical Urgent Care
- ▶ Lifestyle & Wellness – Property Management Services and Home Care Services
- ▶ Health Plans – Medical Emergency Assistance and Euda Society (Doctor's Insurance)

Revenue by Service Care Line, USD'M



# Valuation

## Qualitative and Quantitative Approach



## Quantitative Approach



### 1 Income Approach

Our projections for each service lines are based on various assumptions:

- Roll-out periods
- Growth rates
- Number of members
- Number of transactions
- Fees charged

The underlying revenue and profit forecast are aligned to our strategic expansion plan which covers the expansion of our service lines in existing markets and entry into new markets.

### 2 Market Approach

Comparing trading multiples from a list of companies from the healthcare technology sector.

Implied Enterprise Value Range



# Competitive Strengths & Growth Strategies

Strictly Private & Confidential



# Growth Strategies



## Drive Greater Adoption with our Existing Clients

- Drive greater adoption among existing populations who have become more comfortable with digital health.
- Increase awareness by adding new and complementary products and services.
- Use targeted patient and provider engagement campaigns and best practice training to increase usage across our platform.



## Increase Penetration by Adding New Clients

- Continue to invest in our direct sales force and channel management capabilities.
- Our B2B2C business model is expected to drive higher growth and reduce customer acquisition cost, compared to a direct B2C model.
- Invest heavily in marketing technologies and support staff.



## Invest in New Clinical Specialities and Expand Across Care Settings

- Leverage our highly scalable platform by expanding into new clinical specialties and increase penetration amongst current clients.
- Eliminate the gaps in continuity of care.
- Prove coordinated care along the healthcare continuum.

# Growth Strategies - continued



## Invest in Digitalization and Innovation for Digital Care

- Invest in new technologies to expand the reach of our digital platform.
- Continuous investment in AI technology to expand patient engagement while promoting better care coordination and reducing cost of care.
- Expand use cases by investing in interoperability, including remote patient monitoring, advanced analytics and lab services.



## Leverage Existing Sales Channels and Penetrate New Markets

- Leverage on our highly effective distribution network to commit incremental sales and marketing resources to SMEs to increase our penetration in this market.
- Further penetrate the provider market, notably hospitals and group physician practices.
- Expand into health insurance exchanges, an attractive new sales channel.




## International Expansion and Focused Acquisitions

- Explore joint international offerings with our existing partners and strategic investors.
- Pursue strategic and complementary acquisitions to support our clients' needs.
- Our acquisition strategy focus remains on acquiring technologies, products, capabilities, clinical specialties and distribution channels.

# Growth Potential

## Our Potential Vs Current Market



Source: Markets and Markets, Market Data Forecast; McKinsey & Company: The future of healthcare in Asia: Digital health ecosystems

# Investment Highlights

## Our Value Creation Approach

### Growth Opportunities



- Healthcare expenditure in Asia-Pacific is projected to grow by 7% annually to US\$2.4 trillion by 2022.<sup>1</sup>
- Confluence of healthcare data and AI is accelerating the speed of innovation in healthcare.
- The growing and aging population, increasing prevalence of chronic diseases, and a rise in consumerism among patients.

### Value Creation



- Southeast Asia's first unified AI-driven health and wellness platform.
- Empowering consumers, providers, health systems to improved outcomes, quality and access of healthcare.

### Synergies Realization



- Maximizing revenue growth by achieving economies of scale (expansion of healthcare and wellness service lines across the identified markets).
- Realizing cross-selling opportunities between the service verticals.

### Leverage Growth



- Strategic acquisition to unlock value for shareholders and stakeholders of the company.
- Diverse and extensive network of partners across the region.
- Healthcare assets are attracting greater levels of capital. Investors are drawn to the robust demand of an aging population for healthcare services.


<sup>1</sup> Source: I.E.K.- Expanding into Asia-Pacific.





Thank You

Strictly Private & Confidential





### Company Overview

Singapore-based Healthcare IT company founded in 2019

Growing list of SME and Fortune 500 customers

Currently operating in Singapore

### Transaction Highlights

- Target close: Q4 2022
- Proposed ticker (NASDAQ): EUDA
- Pro forma valuation: \$172M EV
- 8.6x 2023 Revenue
  - 37.7x 2023 EBITDA
- Pro forma ownership:
- EUDA Shareholders: 54%
  - IPO shareholders: 36%
  - Sponsor share: 9%
  - Service providers: 1%

Use of proceeds: Product development and other AI technology research, business expansion, and potential strategic investment opportunities.

### Capital Structure

The transaction is funded by the issuance of 14M new shares to EUDA's shareholders at a deemed value of \$10 per share and contingent earn-outs of 4M shares over the next 2.5 years, ending 31 December 2024 upon EUDA's achievement to a certain share price, revenues and net income.

### Business Overview

Believed to be the first-of-its-kind, a Southeast Asian digital healthcare ecosystem aimed at making healthcare more affordable and accessible, improving patient experience, and delivering better patient outcomes through personalized healthcare.

Proprietary unified AI platform quickly assesses a patient's medical history, triages a medical condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. Aims to build a fully integrated ecosystem for individuals, doctors, insurers, and employers.

Holistic approach supports patients through all stages of care, including wellness & prevention, urgent care & emergencies, pre-existing conditions, and aftercare services.

Key management team members have a combined 100 years of experience in healthcare, technology, insurance, and consumer experience.

Look to expand across Southeast Asia.

### Market Opportunity

Healthcare expenditure in Asia-Pac is projected to grow by 7% annually to US\$2.4 trillion by 2022.

Growing need to minimize travel time, consultation wait time, and provide under-served segments wider access to healthcare



Health-tech usage in Southeast Asia grew 400% in 2020, with user engagement persisting post-lockdown.

Source: Google, Temasek, Bain & Company - e-Economy SEA, 2020

### Competitive Strengths

Disruptive Business Model	Rapid Diversification	Superior AI Driven Back-end	Visionary Management	Expanding Network
Unique <b>ecosystem-based business model</b> integrates a full continuum of healthcare services with data analytics to provide patients with choice of treatment, price transparency, and <b>improved outcomes</b>	<b>Constant diversification</b> into new business verticals to <b>expand cross-selling opportunities</b> and <b>improve monetization channels</b>	<b>Comprehensive data analytics seamlessly distributed</b> across physicians, health plans, and corporate users to provide <b>superior patient experience and informed treatment options</b>	Key management team members have <b>combined 100 years' experience</b> in <b>healthcare, technology, insurance, and consumer experience</b>	Look to expand <b>across Southeast Asia</b>

## Financial Forecast



### Notes:

- Forecasts are based on Base scenario which projects existing services to further expand in Singapore. The existing services are Medical Urgent Care, Property Management Services and Euda Society (Doctor's Insurance).
- The Property Management Service covers the management of properties such as condominiums and shopping malls. Categorized under Home Care Service line from 2023 onward, this service line will eventually evolve to provide home-based medical services to households.
- Growth rates are based on the following assumptions:
  - Economies of scale (expansion of healthcare, lifestyle & wellness service lines and enablement in Singapore);
  - Cross-selling opportunities between the service vertical; and
  - Southeast Asia demands i.e., addressing gaps in the identified markets.
- Surge in revenue growth is aligned with our projected expansion timeline.